News

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. Consistent with Beam’s previously announced data, updated data from seven patients treated with investigational base-editing therapy BEAM-101 demonstrated robust and durable increases i

Traders Rush to Join Fed Rate-Cut Bet Touted by Morgan Stanley

(Bloomberg) -- Wagers in the fed funds futures market on Federal Reserve interest-rate cuts in both December and January have ballooned in size, aided by Morgan Stanley’s endorsement.Most Read from BloombergBrace for a Nationwide Shuffle of Corporate HeadquartersA Chicago Skyscraper Cements the Legacy of a Visionary Postmodern ArchitectCloud Computing Tax Threatens Chicago’s Silicon Valley AmbitionsNYC’s Run-Down Bus Terminal Gets Approval for $10 Billion RevampKansas City Looks Back on its Long

Dow Partners With Macquarie In Gulf Coast Infrastructure Play, Retains Strategic Control

Dow Inc. (NYSE:DOW) shares are trading higher on Monday. The company entered into a definitive agreement to sell a 40% equity stake in select U.S. Gulf Coast infrastructure assets to a fund managed by Macquarie Asset Management. Dow anticipates initial cash proceeds of approximately $2.4 billion from the sale of its 40% equity stake, with potential proceeds reaching up to $3.0 billion if Macquarie Asset Management exercises its option to increase its stake to 49% within six months of closing. Th